Emicizumab
- CAS No.
- 1610943-06-0
- Chemical Name:
- Emicizumab
- Synonyms
- Emicizumab;Imicizumab;ACE 910|||RO 5534262;Research Grade Emicizumab;Emicizumab (anti-Factor IX);Research Grade Emicizumab (DHB87901)
- CBNumber:
- CB93339870
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 7NL2E3F6K3 |
| ATC code | B02BX06 |
Emicizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | CLA1401 | Emicizumab | 1610943-06-0 | 1mg | $5500 | 2026-06-04 | Buy |
| ChemScene | CS-0069970 | Emicizumab 95.00% | 1610943-06-0 | 1mg | $2145 | 2026-06-04 | Buy |
| ChemScene | CS-0069970 | Emicizumab 95.00% | 1610943-06-0 | 5mg | $4290 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1905844 | Emicizumab Antibody 95.9%(SEC-HPLC) | 1610943-06-0 | 1mg | $1430 | 2026-05-06 | Buy |
| Biorbyt Ltd | orb1905844 | Emicizumab Antibody 95.9%(SEC-HPLC) | 1610943-06-0 | 5mg | $2950 | 2026-05-06 | Buy |
Emicizumab Chemical Properties, Uses, Production
Uses
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research[1].
in vivo
Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1].
Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].
| Animal Model: | FVIII-deficient mice[1] |
| Dosage: | 1.5-10 mg/kg |
| Administration: | IV, 24 hours before tail-clip bleeding was performed |
| Result: | Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice. |
References
[1] Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748. DOI:10.1182/blood.2019004334
Emicizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Emicizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Wuhan Sunrise Technology Development Co., Ltd. | 27-027-83314682 13554138826 | whsrtech@vip.163.com | China | 140 | 62 |
| Nanjing Sunlida Biological Technology Co., Ltd. | 025-57798810 18652991625 | sales@sunlidabio.com | China | 3223 | 55 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Hefei Hirisun Pharmatech Co., Ltd. | +86-0551-62678551 15056975894 | sales@hirisunpharm.com | China | 147 | 55 |
| Dideu Industries Group Limited | +8617392712697 | 1022@dideu.com | China | 29089 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| Hubei Weideli Chemical Reagent Co., Ltd. | 18327179646 | 18327179646@163.com | China | 1980 | 58 |
| Jiangsu Greature Bio-Medicine Co., Ltd. | 0512-85557988 18662338937 | frank.wang@greature.com.cn | China | 145 | 58 |
View Latest Price from Emicizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-31 | Emicizumab
1610943-06-0
|
$379.00-1770.00 | 95.9% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Emicizumab
1610943-06-0
- $379.00-1770.00
- 95.9% (SEC-HPLC)
- TargetMol Chemicals Inc.
